- Home
- QS vs BMRN Comparison
QS vs BMRN Comparison
Compare QS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- BMRN
- Stock Information
- Founded
- QS 2010
- BMRN 1996
- Country
- QS United States
- BMRN United States
- Employees
- QS N/A
- BMRN N/A
- Industry
- QS Auto Parts:O.E.M.
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- BMRN Health Care
- Exchange
- QS Nasdaq
- BMRN Nasdaq
- Market Cap
- QS 8.8B
- BMRN 10.0B
- IPO Year
- QS N/A
- BMRN 1999
- Fundamental
- Price
- QS $15.63
- BMRN $53.47
- Analyst Decision
- QS Sell
- BMRN Buy
- Analyst Count
- QS 6
- BMRN 22
- Target Price
- QS $5.88
- BMRN $90.14
- AVG Volume (30 Days)
- QS 55.7M
- BMRN 2.6M
- Earning Date
- QS 10-22-2025
- BMRN 10-27-2025
- Dividend Yield
- QS N/A
- BMRN N/A
- EPS Growth
- QS N/A
- BMRN 60.52
- EPS
- QS N/A
- BMRN 2.69
- Revenue
- QS N/A
- BMRN $3,094,001,000.00
- Revenue This Year
- QS N/A
- BMRN $13.35
- Revenue Next Year
- QS N/A
- BMRN $9.18
- P/E Ratio
- QS N/A
- BMRN $19.91
- Revenue Growth
- QS N/A
- BMRN 12.39
- 52 Week Low
- QS $3.40
- BMRN $51.57
- 52 Week High
- QS $19.07
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- QS 54.92
- BMRN 46.92
- Support Level
- QS $15.02
- BMRN $52.26
- Resistance Level
- QS $17.45
- BMRN $56.80
- Average True Range (ATR)
- QS 1.64
- BMRN 1.55
- MACD
- QS -0.22
- BMRN 0.11
- Stochastic Oscillator
- QS 42.48
- BMRN 36.39
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.